PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2026Clinical and Experimental Gastroenterology0 citationsOpen Access

Irritable Bowel Syndrome Prevalence in Patients with Inflammatory Bowel Disease in Remission: Single-Center Experience

OGOlga GolubovicTITamara Knežević IvanovskiDKDjordje Kralj

Key Points

  • To determine the prevalence of irritable bowel syndrome (IBS) in inflammatory bowel disease (IBD) patients in strict remission.
  • Cross-sectional study conducted at a single center
  • Included 136 patients treated with biologics from December 2022 to June 2023
  • Used stringent definitions for clinical, biologic, and endoscopic remission.
  • 28 (20.6%) patients reported IBS symptoms based on Rome IV criteria
  • IBS prevalence was 27.9% in Crohn’s disease patients versus 13.2% in ulcerative colitis patients (p = 0.034)
  • Females and smokers with Crohn’s disease were more likely to report IBS symptoms.

Abstract

Background: Irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD) are characterized by features of abdominal pain and changes in bowel habits, making it hard to differentiate between the two. Early studies that estimated prevalence of IBS in IBD patients defined remission based only on clinical scores, potentially overestimating IBS symptoms and underestimating subclinical inflammation. The aim of this study was to determine prevalence of IBS in IBD patients who are treated with biologics and have reached clinical, biologic and endoscopic remission, thereby applying a more stringent definition of remission. Methods: This single-center cross-sectional study included 136 patients (68 patients with Crohn’s disease and 68 with ulcerative colitis) who are treated with biologics from December 2022 to June 2023 and have reached clinical, biologic and endoscopic remission. Clinical remission was defined as Crohn’s disease activity index (CDAI) ≤ 150 for patients with Crohn’s disease (CD), and Mayo partial score ≤ 1 for patients with ulcerative colitis (UC). Biologic remission was defined as faecal calprotectin (FCP) ≤ 250 ug/g, and endoscopic remission was defined as the absence of ulcerations for CD and Mayo subscore ≤ 1 for UC patients. The presence of IBS was defined by Rome IV criteria. Results: A total of 28 (20.6%) patients in complete remission reported symptoms consistent with IBS, based on Rome IV criteria. The prevalence of IBS was higher in patients with Crohn’s disease than in those with ulcerative colitis (CD 27.9% (19/68) vs UC 13.2% (9/68), p = 0.034). Females and smokers with Crohn’s disease are more likely to report IBS symptoms. Conclusion: Prevalence of IBS symptoms in IBD patients varies according to how remission is defined. When using stringent clinical, biological and endoscopic remission criteria, 20% of patients present with IBS symptoms, more commonly in those with CD. Keywords: IBS, IBD, prevalence

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Golubovic et al. (2026) studied this question.

synapsesocial.com/papers/6a22672f763171746d545f0ehttps://doi.org/10.2147/ceg.s582517
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P0456Higher prevalence and psychosocial burden of IBS in IBD patients: A Rome IV–based comparative analysis2026
  2. 2Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey2024 · 4 citations
  3. 3Dietary Profile of Patients with Inflammatory Bowel Disease in Clinical Remission—A Preliminary Study2024
  4. 4P1026Rate and predictors of histologic remission in inflammatory bowel disease patients: results from a Romanian prospective cohort2026
  5. 54CPS-046 Evaluation of health impact in infliximab-treated patients with inflammatory bowel disease: incorporation of patient reported outcome measures (PROMs)2024 · 1 citations